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INTRODUCTION: Grading the strength of a body of
diagnostic test evidence involves challenges over and
above those related to grading the evidence from health
care intervention studies. This chapter identifies chal-
lenges and outlines principles for grading the body of
evidence related to diagnostic test performance.
CHALLENGES: Diagnostic test evidence is challenging
to grade because standard tools for grading evidence
were designed for questions about treatment rather
than diagnostic testing; and the clinical usefulness of a
diagnostic test depends on multiple links in a chain of
evidence connecting the performance of a test to
changes in clinical outcomes.
PRINCIPLES: Reviewers grading the strength of a body
of evidence on diagnostic tests should consider the
principle domains of risk of bias, directness, consisten-
cy, and precision, as well as publication bias, dose
response association, plausible unmeasured confound-
ers that would decrease an effect, and strength of
association, similar to what is done to grade evidence
on treatment interventions. Given that most evidence
regarding the clinical value of diagnostic tests is
indirect, an analytic framework must be developed to
clarify the key questions, and strength of evidence for
each link in that framework should be graded separate-
ly. However if reviewers choose to combine domains into
a single grade of evidence, they should explain their
rationale for a particulars u m m a r yg r a d ea n dt h e
relevant domains that were weighed in assigning the
summary grade.
KEY WORDS: grades; diagnostic tests; publication bias; health care
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INTRODUCTION
“Grading” refers to the assessment of the strength of the
body of evidence supporting a given statement or conclu-
sion rather than to the quality of an individual study.
1
Grading can be valuable for providing information to
decisionmakers, such as guideline panels, clinicians, care-
givers, insurers and patients who wish to use an evidence
synthesis to promote improved patient outcomes.
1,2 In
particular, such grades allow decisionmakers to assess the
degree to which any decision can be based on bodies of
evidence that are of high, moderate, or only low strength of
evidence. That is, decisionmakers can make a more
defensible recommendation about the use of the given
intervention or test than they might make without the
strength of evidence grade.
The Evidence-based Practice Center (EPC) Program
supported by the Agency for Healthcare Research and
Quality (AHRQ) has published guidance on assessing the
strength of a body of evidence when comparing medical
interventions.
1,3 That guidance is based on the principles
identified by the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) working
group
4–6with minor adaptations for EPCs. It is important
to distinguish between the quality of a study and the
strength of a body of evidence on diagnostic tests as
assessed by the GRADE and EPC approaches. EPCs
consider “The extent to which all aspects of a study’s
design and conduct can be shown to protect against
systematic bias, nonsystematic bias, and inferential error”
as the quality or internal validity or risk of bias of an
individual study.
7 In contrast to the GRADE approach, the
EPC approach prefers to use the term “strength of evidence”
instead of “quality of evidence” to describe the grade of an
evidence base for a given outcome because the latter term is
often equated with the quality of individual studies without
consideration of the other domains for grading a body of
evidence. An assessment of the strength of the entire body
of evidence includes an assessment of the quality of an
individual study along with other domains. Although the
GRADE approach can be used to make judgments about the
strength of an evidence base and the strength of recom-
mendations, this chapter considers using GRADE as a tool
for assessing only the strength of an evidence base.
When assessing the strength of an evidence base,
systematic reviewers should consider four principle
domains—risk of bias, consistency, directness, and preci-
JGIM
S47sion.
5Additionally, reviewers may wish to consider publi-
cation bias as a fifth principle domain as recently suggested
by the GRADE approach.
6 Additional domains to consider
are dose-response association, existence of plausible un-
measured confounders, and strength of association (i.e.,
magnitude of effect). Of note, GRADE considers applica-
bility as an element of directness. This is distinct from the
EPC approach, which encourages users to evaluate appli-
cability as a separate component.
EPCs grade the strength of evidence for each of the
relevant outcomes and comparisons identified in the key
questions addressed in a systematic review. The process of
defining the important intermediate and clinical outcomes
of interest for diagnostic tests is further described in a
previous article.
8 Because most diagnostic test literature
focuses on test performance (e.g., sensitivity and specific-
ity), at least one key question will normally relate to that
evidence. In the uncommon circumstance in which a
diagnostic test is studied in the context of a clinical trial
(e.g., test versus no test) with clinical outcomes as the study
endpoint, the reader is referred to the Methods Guide for
Effectiveness and Comparative Effectiveness Reviews on
evaluating interventions.
1,3 For other key questions, such as
those related to analytic validity, clinical validity, and
clinical utility, the principles described in the present
document and the Methods Guide for Effectiveness and
Comparative Effectiveness Reviews should apply.
This paper is meant to complement the EPC Methods
Guide for Comparative Effectiveness Reviews, and not to
be a complete review. Although we have written this paper
to serve as guidance for EPCs, we also intend for this to be
a useful resource for other investigators interested in
conducting systematic reviews on diagnostic tests. In this
paper, we outline the particular challenges that systematic
reviewers face in grading the strength of a body of evidence
on diagnostic test performance. The focus of this article will
be on diagnostic tests, meaning tests that are used in the
diagnostic and management strategy of a patient symptom
or complaint, as opposed to prognostic tests, which are for
predicting responsiveness to treatment. We then propose
principles for addressing these challenges.
COMMON CHALLENGES
Diagnostic test studies commonly focus on accuracy of the
test to make a disease diagnosis, and the task of grading this
body of evidence is a challenge in itself. Through
discussion with EPC investigators and a review of recent
EPC reports on diagnostic tests,
9–13 we identified common
challenges that reviewers face when assessing the strength
of a body of evidence on diagnostic test performance.
One common challenge is that standard tools for
assessing the quality of a body of evidence associated with
an intervention—in which the body of evidence typically
relates directly to the overarching key question—are not so
easily applied to a body of evidence associated with a
diagnostic test, where evidence is often indirect. Indeed, this
is the reason that establishing a logical chain with an
analytic framework and the associated key questions is
particularly important for evaluating a diagnostic test (see
Paper 2).
8 It is also the reason we must assess the strength
of the body of evidence for each link in the chain. The
strength of the body of evidence regarding the overarching
question of whether a test will improve clinical outcomes
depends both on the total body of evidence, as well as the
body of evidence for the weakest link in this chain.
Although there is a temptation to use diagnostic accuracy
as an intermediate outcome for the effect of a diagnostic test
on clinical outcomes, there is often no direct linkage
between the diagnostic accuracy outcome and a clinical
outcome. This is particularly challenging when tests are
used as a part of an algorithm. While rates of false
positives and false negatives may be directly related to
adverse effects or harms, other accuracy outcomes such as
sensitivity or specificity may not directly correlate to
effective management and treatment of disease, especially
when the test under question is not directly linked to the
use of an established treatment algorithm. When tests are
used in regular practice not for final diagnosis and
treatment, but as a triage for further testing, then accuracy
of diagnosis is less important than accuracy of risk
classification.
A second challenge arises in the application of the
strength of evidence domains for studies of diagnostic tests.
For example, in assessing the precision of estimates of test
performance, it is particularly difficult to judge whether a
particular confidence interval is sufficiently precise; be-
cause of the logarithmic nature of diagnostic performance
measurements—such as sensitivity, specificity, likelihood
ratios, and diagnostic odds ratios—even a relatively wide
confidence interval suggesting imprecision may not neces-
sarily translate into imprecision that is clinically meaning-
ful. Table 1 shows an example where a 10% reduction in
the sensitivity of various biopsy techniques (from 98% to
88% in the far right column) changes the estimated
probability of having cancer after a negative test by less
than 5%.
11
PRINCIPLES FOR ADDRESSING THE CHALLENGES
Principle 1. Methods for grading intervention studies can
be adapted for studies evaluating studies on diagnostic tests
with clinical outcomes
A body of evidence evaluating diagnostic test outcomes
such as diagnostic thinking, therapeutic choice, and clinical
S48 Singh et al.: Grading a Body of Evidence on Diagnostic Tests JGIMoutcomes can be assessed in very much the same way as a
body of evidence evaluating outcomes of therapeutic
interventions. Grading issues in this type of diagnostic test
study are more straightforward than in studies measuring
accuracy outcomes. Although this is rarely done, the effect
of tests on the clinical outcomes described above can be
assessed directly with trial evidence. In cases where trial
evidence is available, application of the grading criteria,
such as GRADE, should not significantly differ from the
methods used for intervention evidence.
An unresolved issue is what to do when there is no direct
evidence available linking the test to the outcome of
interest. For grading intervention studies, the use of
intermediate outcomes, such as accuracy outcomes, would
be considered “indirect” evidence and would reduce the
strength of the grade. The linkage of accuracy outcomes
such as true positives and false positives to clinical
outcomes depend in part upon the benefits and harms of
available treatments as well as the cognitive or emotional
outcomes resulting from the knowledge itself, as outlined in
a previous article [ref Segal et al.].
14
Currently there is no consensus for one particular
approach to grading an overall body of evidence when it
is entirely indirect, such as when only studies of accuracy
are available. As discussed in a previous article,
8 there are
circumstances in which accuracy outcomes may be suffi-
cient to conclude that there is or is not a benefit on clinical
outcomes.
15 In other cases in which only indirect evidence
on intermediate accuracy outcomes is available, EPCs
should discuss with decisionmakers and methodologists
the benefits of including such indirect evidence and the
specific methods to be used.
Principle 2. Consider carefully what test characteristic
measures are the most appropriate intermediate outcomes
for assessing the impact of a test on clinical outcomes and
their precision in the clinical context represented by the key
question.
Consistent with EPC and GRADE principles of empha-
sizing the patient important outcomes, reviewers should
consider how any surrogates such as accuracy outcomes
will lead to changes in clinical outcomes. Use of an analytic
framework and decision models as described in paper two
[ref Samson et al.],
8 help to clarify the linkage between
accuracy outcomes and clinical outcomes for systematic
reviewers, and users of systematic reviews alike.
If accuracy outcomes are presented as true positives, true
negatives, false positives, and false negatives, then they can
be easily translated into other accuracy outcomes such as
sensitivity and specificity, positive predictive value (PPV)
and negative predictive value (NPV). Systematic reviewers
need to carefully consider which of these accuracy out-
comes to assess based on which outcome will relate most
directly to clinical outcomes as well as necessary levels of
precision.
Sometimes it is more important to “rule out” a particular
disease that has severe consequences if missed. In these
cases, use of a triage test with high sensitivity and NPV
may be what is most important, and actual diagnosis of a
particular disease is less important.
When the treatment of a disease has high associated risks,
multiple tests are often used to assure the highest accuracy.
Tests used in isolation need to have both high sensitivity
and specificity, or high PPVand NPV, but if no such test is
available, clinicians may be interested in the added benefits
and harms of “adding-on” a test. The accuracy outcome of
interest of these tests would primarily be high specificity or
PPV.
Tests that are more invasive will naturally have greater
harms. Additional harms may result from misdiagnosis, so
it is almost always important to consider the measurement
of false positives and false negatives when assessing the
harms of a diagnostic test. The degree of harms from false
negatives depend on the severity of disease if there is a
missed diagnosis, in addition to the risks from the testing
itself (i.e. if the test is invasive and associated with risks in
and of itself). The degree of harms from false positives
depends on the invasiveness of further testing or treatment,
as well as the emotional and cognitive effects of inaccurate
disease labeling.
Table 1. Example of the Impact of Precision of Sensitivity on Negative Predictive Value
Type of biopsy Post biopsy probability of having cancer after a negative core-needle biopsy result
a
Analysis
results
Analysis overestimated
sensitivity by 1%
(e.g., sensitivity 97%
rather than 98%)
Analysis overestimated
sensitivity by 5%
(e.g., sensitivity 93%
rather than 98%)
Analysis overestimated
sensitivity by 10%
(e.g., sensitivity 88%
rather than 98%)
Freehand automated gun 6% 6% 8% 9%
Ultrasound guidance automated gun 1% 1% 3% 5%
Stereotactic guidance automated gun 1% 1% 3% 5%
Ultrasound guidance vacuum-assisted 2% 2% 3% 6%
Stereotactic guidance vacuum-assisted 0.4% 0.8% 3% 5%
aFor a woman with a BI-RADS® 4 score following mammography and expected to have an approximate prebiopsy risk of malignancy of 30%.
Note that an individual woman’s risk may be different from these estimates depending on her own individual characteristics
11
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data regarding the value of outcomes resulting from true
positive test result, as well as true negative, false positive
and false negative results. In a simple decision model it
is possible to identify a threshold line for the combina-
tions of test sensitivity and specificity for which testing
vs. not testing is a toss-up—where net benefits are
equivalent to net harms. To the extent that the confidence
intervals for sensitivity and specificity derived from the
body of evidence are contained within one territory or the
other (“testing better”, as in this illustration), these
intervals are sufficiently precise for purposes of decision
making.
16
Of course, this formulation is a simplification for
many situations. Tests are rarely used alone to diagnosis
disease and determining treatment choices, but are more
often used as part of an algorithm of testing and
management. The accuracy outcome of most interest
depends on how the test is used in a clinical algorithm,
as well as the mechanism by which the test could improve
clinical outcomes or cause harms. Whether or not one uses
a decision model to help sort out these issues, considering
the important test characteristics and their precision in the
clinical context represented by the key question is a
necessary step in the process of assessing a body of
evidence.
Principle 3. The principle domains of GRADE can be
adapted to assess a body of evidence on diagnostic test
accuracy.
To assess a body of evidence related to diagnostic test
performance, we can adapt the GRADE’s principle domains
of risk of bias, consistency, directness, and precision.
(Table 2) Evaluating risk of bias includes considerations
of how the study type and study design and conduct may
have contributed to systematic bias. The potential sources
of bias relevant to diagnostic test performance and strategies
for assessing the risk of systematic error in such studies are
discussed in a previous article [ref Santaguida et al.].
17
Diagnostic tests, particularly laboratory tests, can yield
heterogeneous results due to different technical methods.
For example, studies may report using different antibodies
for immunoassays, or standards with different values and
units assigned to them.
Consistency concerns homogeneity in the direction and
magnitude of results across different studies. The concept
can be similarly applied to diagnostic test performance
studies, although the method of measurement may differ.
For example, consistency among intervention studies with
quantitative data may be assessed visually with a forest plot.
However, for diagnostic test performance reviews, the most
common presentation format is a summary receiver operat-
ing characteristic (ROC) curve, which displays the sensi-
tivity and specificity results from various studies. A bubble
plot of true positive versus false positive rates showing
spread in ROC space is one method of assessing the
consistency of diagnostic accuracy among studies. As with
intervention studies, the strength of evidence is reduced by
unexplained heterogeneity—that is, heterogeneity not
explained by different study designs, methodologic quality
of studies, diversity in subject characteristics, or study
context.
Directness, according to AHRQ’s Methods Guide for
Effectiveness and Comparative Effectiveness Reviews,
3
occurs when the evidence being assessed “reflects a single,
direct link between the interventions of interest [diagnostic
tests] and the ultimate health outcome under consider-
ation.”
1 When assessing the directness of the overarching
question, if there are no studies linking the test to a clinical
outcome, then evidence that only provides diagnostic
accuracy outcomes would be considered indirect. If the
decision is made to grade the strength of evidence of an
intermediate outcome such as diagnostic accuracy, then the
reviewer does not need to automatically “downgrade” that
outcome for being indirect. Of note, directness does apply
to how a test is used in comparison to another test. For
example, a study may compare the use of a d-dimer test as a
replacement to venous ultrasound for the diagnosis of
venous thromboembolism, but in actual practice the
relevant question may be the comparison of d-dimer test
as a triage for venous ultrasound compared to the use of
ultrasound alone. It is worth noting EPCs consider some
aspects of directness separately as described in the
applicability chapter [Hartmann et al.].
18 Although not
included when EPCs assess directness or the strength of
evidence, other schemas, such as GRADE, rate directness
based on whether the test evaluated is not the exact test
used in practice, or if the test accuracy is being calculated in
a population or for a use (diagnosis, prognosis, etc.) that is
different than the population or use evaluated in the report.
Because EPC reports are intended to be used by a broad
spectrum of stakeholders, describing the applicability of the
evidence on these factors allows the decision-makers to
consider how the evidence relates to their test and
population.
Precision refers to the width of confidence intervals for
diagnostic accuracy measurements and is integrally related
to sample size.
1 Before downgrading the strength of an
evidence base for imprecision, reviewers could consider
how imprecision for one measure of accuracy may impact
clinically meaningful outcomes. This may involve a simple
calculation of posttest probabilities over a range of values
for sensitivity and specificity, as shown in Table 1,o r ,a s
illustrated above, a more formal analysis with a decision
model (see Trikalinos et al.).
19 If the impact of imprecision
on clinical outcomes is negligible or if the demonstrated
precision is sufficient to make the decision, the evidence
should not be downgraded.
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Domain Definition and Elements Application to evaluation of diagnostic
test performance
Risk of Bias Risk of bias is the degree to which the included studies
for a given outcome or comparison have a high
likelihood of adequate protection against bias
(i.e., good internal validity), assessed through
main elements:
Use one of three levels of aggregate risk of bias:
￿ Study design (e.g., RCTs or observational studies) ￿ Low risk of bias
￿ Aggregate quality of the studies under consideration
from the rating of quality (good/fair/poor) done for
individual studies
￿ Medium risk of bias
￿ High risk of bias
Well designed and executed studies of new tests
compared to an adequate criterion standard are rated
as “low risk of bias”
Consistency Consistency is the degree to which reported study
results (e.g., sensitivity, specificity, likelihood ratios)
from included studies are similar. This can be assessed
through two main elements:
Use one of three levels of consistency:
￿ The range of study results is narrow ￿ Consistent (i.e., no inconsistency)
￿ Variability in study results is explained by differences
in study design, patient population or test variability
￿ Inconsistent
￿ Unknown or not applicable (e.g., single study)
Single-study evidence bases should be considered as
“consistency unknown (single study).”
Directness Directness relates to whether the evidence links the
interventions directly to outcomes. For a comparison
of two diagnostic tests, directness implies head-to-head
comparisons against a common criterion standard
Score dichotomously as one of two levels of directness
Directness may be contingent on the outcomes of interest ￿ Direct
￿ Indirect
When assessing the directness of the overarching
question, if there are no studies linking the test to a
clinical outcome, then evidence that only provides
diagnostic accuracy outcomes would be considered
indirect. If indirect, specify which of the two types
of indirectness account for the rating (or both, if that
is the case)—namely, use of intermediate/ surrogate
outcomes rather than health outcomes, and use of
indirect comparisons. If the decision is made to
grade the strength of evidence of an intermediate
outcome such as diagnostic accuracy, then the
reviewer does not need to automatically “downgrade”
that outcome for being indirect
Precision Precision is the degree of certainty surrounding an
effect estimate with respect to a given outcome
(i.e., for each outcome separately)
Score dichotomously as one of two levels of precision:
If a meta-analysis was performed, this will be the
confidence interval around the summary measure(s)
of test performance (e.g sensitivity, true positive)
￿ Precise
￿ Imprecise
A precise estimate is an estimate that would allow a
clinically useful conclusion. An imprecise estimate is
one for which the confidence interval is wide enough
to include clinically distinct conclusions
Publication bias† Publication bias indicates that studies may have been
published selectively, with the result that the estimate
of test performance based on published studies does
not reflect the true effect. Methods to detect publication
bias for medical test studies are not robust. Evidence
from small studies of new tests or asymmetry in funnel
plots should raise suspicion for publication bias
Publication bias can influence ratings of consistency,
precision, magnitude of effect (and, to a lesser degree,
risk of bias and directness). Reviewers should
comment on publication bias when circumstances
suggest that relevant empirical findings, particularly
negative or no-difference findings, have not been
published or are unavailable
Dose-response
association
This association, either across or within studies, refers
to a pattern of a larger effect with greater exposure
(dose, duration, and adherence)
The dose-response association may support an
underlying mechanism of detection and potential
relevance for some tests that have continuous
outcomes and possibly multiple cutoffs
[e.g., gene expression, serum PSA (prostate-specific
antigen) levels, and ventilation/perfusion scanning]
Plausible unmeasured
confounding and bias
that would decrease
an observed effect
or increase an effect
if none was observed
Occasionally, in an observational study, plausible
confounding factors would work in the direction
opposite to that of the observed effect. Had these
confounders not been present, the observed effect
would have larger. In such case the evidence can
be upgraded
The impact of plausible unmeasured confounders may
be relevant to testing strategies that predict outcomes.
A study may be biased to find low diagnostic
accuracy via spectrum bias and yet despite this find
very high diagnostic accuracy
(continued on next page)
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assess a body of evidence on diagnostic test accuracy.
When grading a body of evidence about a diagnostic test,
additional domains should be considered. These additional
domains are summarized in Table 2.
1–3 These additional
domains include publication bias, dose-response associa-
tion, existence of plausible unmeasured confounders, and
strength of association. Reviewers should comment on
publication bias when circumstances suggest that negative
or no-difference findings have not been published or are
unavailable. The dose-response association may support an
underlying mechanism of detection and potential relevance
for some tests that have continuous outcomes and possibly
multiple cutoffs (e.g., gene expression, serum PSA [pros-
tate-specific antigen] levels, and ventilation/perfusion scan-
ning). The impact of plausible unmeasured confounders
may be relevant to testing strategies that predict outcomes.
A study may be biased to find low diagnostic accuracy via
spectrum bias and yet despite this find very high diagnostic
accuracy. The strength of association may be relevant when
comparing the accuracy of two different diagnostic tests
with one being more accurate than the other.
Principle 5. Multiple domains should be incorporated into
an overall assessment in a transparent way
The overall strength of evidence reflects a global
assessment of the principle domains and any additional
domains, as needed, into an overall summary grade—high,
moderate, low, or insufficient evidence. The focus should
be on providing an overall grade for the relevant key
question link in the analytic chain or for outcomes
considered relevant for patients and decisionmakers. These
should ideally be identified a priori. Consideration should
be given on how to incorporate multiple domains into the
overall assessment.
There is no empirical evidence to suggest any difference
in assigning a summary grade based on qualitative versus
quantitative approaches. GRADE advocates an ordinal
approach with a ranking from high, moderate, or low, to
very low. These “grades” or “overall ratings” are developed
using the eight domains suggested by GRADE. The EPC
approach for intervention studies described in the Methods
Guide for Effectiveness and Comparative Effectiveness
Reviews
1,3 allows for more flexibility on grading the
strength of evidence. Whichever approach reviewers choose
for diagnostic tests, they should consider describing their
rationale for which of the required domains were weighted
the most in assigning the summary grades.
ILLUSTRATION
An illustration in Table 3 provides guidance on how
reviewers should approach grading a body of evidence on
diagnostic test accuracy. This is adapted from the GRADE
approach and the EPC Methods Guide for Comparative
Effectiveness Reviews. Reviewers should carefully consider
which accuracy outcomes are linked to clinical outcomes.
In choosing the accuracy outcomes, if the diagnostic test is
followed by an invasive procedure, then the number of false
positives may be considered most important. However
when “diagnostic tests” are used as part of a management
strategy, consideration should also be given to grading the
positive predictive value and the negative predictive value
or likelihood ratios if these additional outcomes assist
decision makers. An additional example of grading for
positive predictive value and negative predictive value is
shown in the norovirus table below (Table 4).
20,21This table
illustrates how presentation of the same information in
different ways can be helpful in considering how to link the
accuracy outcomes to clinical practice and projecting how
the test would impact clinical outcomes.
Another review on the use of non-invasive imaging in
addition to standard workup after recall for evaluation of a
breast lesion detected on screening mammography or
physical examination illustrates how accuracy does not
relate to outcomes when it is being used as part of an
algorithm of whether to treat versus watchful waiting.
13
This evidence review focused on the non-invasive imaging
studies intended to guide patient management decisions
after the discovery of a possible abnormality. The studies
were intended to provide additional information to enable
Table 2. (continued)
Domain Definition and Elements Application to evaluation of diagnostic
test performance
Strength of association
(magnitude of effect)
Strength of association refers to the likelihood that the
observed effect or association is large enough that it
cannot have occurred solely as a result of bias from
potential confounding factors
The strength of association may be relevant when
comparing the accuracy of two different medical tests
with one being more accurate than the other
It is possible that the accuracy of a test is better than the
reference standard because of an imperfect reference
standard. It is important to consider this and modify
the analysis to take into consideration alternative
assumptions about the best reference standard
*Adapted from the Methods Guide for Effectiveness and Comparative Effectiveness Reviews
3
†The GRADE approach is moving towards considering publication bias a GRADE principle domain
Abbreviations: EPC = Evidence-based Practice Center
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waiting,” or “return to normal screening intervals” care
pathways. Thus the usual strategy of assuming the clinical
outcome would be simply a downgrade of the surrogate
doesn’t always hold true. Reviewers should evaluate the
surrogate in the context of the clinical outcome. As the table
on summary of key findings in the evidence report
illustrates, despite the accuracy of the exact diagnosis being
Table 3. Steps in Grading a Body of Evidence on Diagnostic Test Accuracy Outcomes
*Adapted from the Methods Guide for Effectiveness and Comparative Effectiveness Reviews
3
Table 4. Illustration of the Approach to Grading a Body of Evidence on Diagnostic Tests- Identifying Norovirus in a Healthcare Setting *
Outcome Quantity
and type
of evidence
Findings Starting
grade
Decrease GRADE‡ GRADE of
Evidence for
Outcome
Overall
GRADE§
Risk of
Bias‡
Consistency‡ Directness‡ Precision‡ Publication
Bias‡
Sensitivity† 1 DIAG 68% High 0 0 0 -1 0 Moderate Moderate
Specificity† 1 DIAG 99% High 0 0 0 -1 0 Moderate
PPV† 1 DIAG 97% High 0 0 0 -1 0 Moderate
NPV† 1 DIAG 82% High 0 0 0 -1 0 Moderate
*Adapted from MacCannell T, Umscheid CA, Agarwal RK, Lee I, Kuntz G, Stevenson, KB, and the Healthcare Infection Control Practices Advisory
Committee. Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. Infection Control and Hospital
Epidemiology. 2011; 32(
10): 939-969
20
21
†These outcomes were considered the most critical by the guideline developers
‡These modifiers can impact the GRADE by 1 or 2 points
§Consider the additional domains of strength of association, dose-response and impact of plausible confounders if applicable
S53 Singh et al.: Grading a Body of Evidence on Diagnostic Tests JGIMlow, clinical management may be the same if the post-test
probability did not cross a certain decision threshold to alter
management decisions.
Two reviewers should independently score these relevant
major outcomes and comparisons, within each key question.
They should consider the principle domains of directness,
precision, consistency, risk of bias, and publication bias, as
well as dose response association, strength of association,
and impact of unmeasured confounders. Reviewers should
explicitly assess each domain to arrive at a grade for each
outcome. Reviewer’s choice of various accuracy outcomes
to grade may affect how the various domains of directness,
precision and consistency are assessed. This is illustrated in
the example by the GRADE working group about multi-
splice coronary CT scans as compared to coronary
angiography.
4 Evidence was considered direct for certain
accuracy outcome such as true positives, true negatives, and
false positives since there was little uncertainity about the
clinical implications of these results. However, since there
was uncertainity about the clinical implications of a false
negative test result, this was considered indirect.
4 This
resulted in a low strength of evidence grade for false
negatives as compared to moderate for other accuracy
outcomes.
It is reasonable to consider either a more flexible
qualitative approach to grading or the standard ordinal
approach ranging from high to insufficient strength of
evidence. Reviewers should resolve differences in domain
assessments and grades of outcomes and describe how the
consensus score was reached (e.g., by discussion or by
third-party adjudication). If appropriate they should con-
sider arriving at a single summary grade for the diagnostic
test through transparent and systematic methods. If
reviewers chose to assign an overall summary grade they
should consider the impact of various accuracy outcomes
on the overall strength of evidence grade and identify
which of these accuracy outcomes was considered “key”.
SUMMARY
Grading the strength of a body of diagnostic test evidence
involves challenges over and above those related to grading
the evidence from therapeutic intervention studies. The
greatest challenge appears to be assessing multiple links in a
chain of evidence connecting the performance of a test to
changes in clinical outcomes. In this chapter, we focused
primarily on grading the body of evidence related to a
crucial link in the chain—diagnostic test performance—and
described less fully the challenges involved in assessing
other links in the chain.
No one system for grading the strength of evidence
for diagnostic tests has been shown to be superior to any
other and many are still early in development. However,
we conclude that, in the interim, applying the consistent
and transparent system of grading using the domains
described above, and giving an explicit rationale for the
choice of grades based on these domains, will make EPC
and other reports on diagnostic tests more useful for
decisionmakers.
KEY POINTS
￿ One can use GRADE for diagnostic tests. The outcomes
one should consider are the clinical outcomes of
effectiveness or harm if available for diagnostic tests.
￿ When intermediate accuracy outcomes are used, an
analytic framework should describe how the test is
related to clinical outcomes, and then delineate the
individual questions that can be answered in that
framework
￿ Selection of accuracy outcomes (i.e. sensitivity, specific-
ity, positive predictive value and negative predictive
value, true positives, true negatives, false positives, and
false negatives) and needed levels of precision of these
quantities should consider how the test is to be used in
the clinical context.
￿ Domains of risk of bias, directness, consistency, precision,
publication bias, dose response association, and plausible
unmeasured confounders can be used to grade the strength
of evidence for the effect of a diagnostic test on clinical
outcomes or on intermediate surrogate outcomes if selected
by the EPC and key informants.
￿ Whether reviewers choose a qualitative or quantitative
approach to combining domains into a single grade, they
should consider explaining their rationale for a particular
summary grade and the relevant domains that were
weighted the most in assigning the summary grade.
ACKNOWLEDGMENTS: This report is based on research con-
ducted by the Johns Hopkins Evidence-based Practice Center
under contract to the Agency for Healthcare Research and Quality
(AHRQ), Rockville, MD. The findings and conclusions in this
document are those of the author(s), who are responsible for its
content, and do not necessarily represent the views of AHRQ. No
statement in this report should be construed as an official position
of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help clinicians,
employers, policymakers, and others make informed decisions
about the provision of health care services. This report is intended
as a reference and not as a substitute for clinical judgment. This
report may be used, in whole or in part, as the basis for the
development of clinical practice guidelines and other quality
enhancement tools, or as a basis for reimbursement and coverage
policies. AHRQ or U.S. Department of Health and Human Services
endorsement of such derivative products or actions may not be
stated or implied.
The authors would like to acknowledge the contribution of
Dr Mark Helfand (Oregon Evidence-based Practice Center), Dr Joseph
Lau (Tufts Evidence-based Practice Center) Dr Jonathan Treadwell
(ECRI Institute Evidence-based Practice Center), Dr Kathleen N. Lohr
(RTI International) and Dr Douglas K Owens (Stanford University) for
providing comments on a draft of the manuscript.
S54 Singh et al.: Grading a Body of Evidence on Diagnostic Tests JGIMConflict of Interest: The authors declare that they do not have a
conflict of interest.
Open Access: This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Corresponding Author: Sonal Singh, MD, MPH; Department of
Medicine, Johns Hopkins University School of Medicine, 624 N
Broadway, Rm 680 B, Baltimore, MD 21205, USA
(e-mail: Ssingh31@jhu.edu).
REFERENCES
1. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the
strength of a body of evidence when comparing medical interventions–
Agency for Healthcare Research and Quality and the Effective Health-
Care Program. J Clin Epidemiol. 2010;63(5):513–23.
2. Atkins D, Fink K, Slutsky J. Better information for better health care:
the evidence-based practice center program and the Agency for Health-
care Research and Quality. Ann Intern Med. 2005;142(12 Pt 2):1035–41.
3. Agency for Healthcare Research and Quality. Methods Guide for
Effectiveness and Comparative Effectiveness Reviews. Rockville, MD:
Agency for Healthcare Research and Quality. Available at: http://www.
effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-
reports/?pageaction=displayproduct&productid=318. December, 2011.
4. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of
evidence and strength of recommendations for diagnostic tests and
strategies. BMJ. 2008;336(7653):1106–10.
5. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus
on rating quality of evidence and strength of recommendations. BMJ.
2008;336(7650):924–6.
6. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek
J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE
guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64
(4):401–6.
7. Lohr KN, Carey TS. Assessing “best evidence”: issues in grading the
quality of studies for systematic reviews. Jt Comm J Qual Improv.
1999;25:470–9.
8. Samson D, Schoelles KM. Chapter 2: Medical tests guidance (2)
developing the topi and structuring systematic reviews of medical tests:
utility of PICOTS, analytic frameworks, decision trees, and other frame-
works. J Gen Internal Med. 2012. doi:10.1007/s11606-012-2007-7.
9. Marchionni L, Wilson RF, Marinopoulos SS, et al. Impact of gene
expression profiling tests on breast cancer outcomes. Evidence report/
technology assessment No. 160. (Prepared by The Johns Hopkins University
Evidence-based Practice Center under contract No. 290-02-0018). AHRQ
Publication No. 08-E002. Rockville, MD: Agency for Healthcare Research
and Quality. January 2008. Available at: www.ahrq.gov/downloads/pub/
evidence/pdf/brcancergene/brcangene.pdf. Accessed December, 2011.
10. Ross SD, Allen IE, Harrison KJ, et al. Systematic review of the literature
regarding the diagnosis of sleep apnea. Evidence report/technology assess-
ment No. 1. (Prepared by MetaWorks Inc. under Contract No. 290-97-0016.)
AHCPR Publication No. 99-E002. Rockville, MD: Agency for Health Care
Policy and Research. February 1999. Available at: www.ncbi.nlm.nih.gov/
bookshelf/br.fcgi?book=erta1. Accessed December, 2011.
11. Bruening W, Schoelles K, Treadwell J, et al. Comparative effectiveness
of core-needle and open surgical biopsy for the diagnosis of breast
lesions. Comparative effectiveness review No. 19. (Prepared by ECRI
Institute Evidence-based Practice Center under Contract No. 290-02-
0019.) Rockville, MD: Agency for Healthcare Research and Quality.
December 2009. Available at: http://effectivehealthcare.ahrq.gov/ehc/
products/17/370/finalbodyforposting.pdf. Accessed December, 2011.
12. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing
in adults with a history of venous thromboembolism. Evidence
report/technology assessment No. 180. (Prepared by Johns Hopkins
University Evidence-based Practice Center under Contract No. HHSA
290-2007-10061-I). AHRQ Publication No. 09-E011. Rockville, MD.
Agency for Healthcare Research and Quality. June 2009. Available at:
http://www.ahrq.gov/downloads/pub/evidence/pdf/factorvleiden/
fvl.pdf. Accessed December, 2011.
13. Bruening W, Uhl S, Fontanarosa J, Reston J, Treadwell J, Schoelles
K. Noninvasive Diagnostic Tests for Breast Abnormalities: Update of a
2006 Review. Comparative Effectiveness Review No. 47. (Prepared by the
ECRI Institute Evidence-based Practice Center under Contract No. 290-
02-0019.) AHRQ Publication No. 12-EHC014-EF. Rockville, MD: Agency
for Healthcare Research and Quality; February 2012.
14. Segal JB. Chapter 3: Choosing the important outcomes for a systematic
review of a medical test. J Gen Internal Med. 2011. doi:10.1007/s11606-
011-1802-x.
15. Lord SJ, Irwig L, Simes J. When is measuring sensitivity and specificity
sufficient to evaluate a diagnostic test, and when do we need a
randomized trial? Ann Intern Med. 2006;144(11):850–5.
16. Pauker SG, Kassirer JP. The threshold approach to clinical decision
making. N Engl J Med. 1980;302(20):1109–17.
17. Santaguida PL, Riley CM, Matchar DB. Chapter 5: Assessing risk of
bias as a domain of quality in medical test studies. J Gen Intern Med.
2012.
18. Hartmann KE, Matchar DB, Chang S. Chapter 6: Assessing applicabil-
ity of medical test studies in systematic reviews. J Gen Internal Med.
2012. doi:10.1007/s11606-011-1961-9.
19. Trikalinos TA, Kulasingam S, Lawrence WH. Chapter 10: Deciding
whether to complement asystematic review of medical tests with decision
making. J Gen Intern Med. 2012.
20. MacCannell T, Umscheid CA, Agarwal RK, Lee I, Kuntz G, Stevenson
KB, the Healthcare Infection Control Practices Advisory Commit-
tee. Guideline for the prevention and control of norovirus gastroenteritis
outbreaks in healthcare settings. Infect Control Hosp Epidemiol.
2011;32(10):939–69.
21. Turcios RM, Widdowson MA, Sulka AC, Mead PS, Glass RI. Reevalu-
ation of epidemiological criteria for identifying outbreaks of acute
gastroenteritis due to norovirus: United States, 1998-2000. Clin Infect
Dis. 2006;42(7):964–9.
S55 Singh et al.: Grading a Body of Evidence on Diagnostic Tests JGIM